Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rot colon carcinoma model by Vrie, W. (Wim) van de et al.
J Cancer Res Clin Oncol (1996) 122:403-408 9 Springer-Verlag 1996 
W. Van de Vrie 9 J. H. M. Schellens 
W. J. Loos 9 H. J. Kolker 9 J. Verwey 
G. Stoter 9 N. M. C. Durante 9 A. M. M. Eggermont 
Modulation of multidrug resistance with dexniguldipine hydrochloride 
(B8509-035) in the CC531 rat colon carcinoma model 
Received: 8 September 1995/Accepted: 10 January 1996 
Abstract The chemosensitizing potency of dexnigul- 
dipine hydrochloride (B8509-035) on epidoxorubicin 
was assessed in a multidrug-resistant (MDR) tumour 
model, the intrinsic MDR rat colon carcinoma CC531. 
In vitro in the sulphorhodamine B cell-viability assay 
the cytotoxicity of epidoxorubicin was increased ap- 
proximately 15-fold by co-incubation with 50 ng/ml 
dexniguldipine. In vivo concentrations of dexnigul- 
dipine 5 h after a single oral dose of 30 mg/kg were 72 
(+ 19 SD) ng/ml in plasma nd 925 (_+ 495 SD) ng/g in 
tumour tissue. Levels of the metabolite of dexnigul- 
dipine, M-l, which has the same chemosensitizing po- 
tential, were 26 (_+ 6 SD) ng/ml and 289 (_+ 127 SD) 
ng/g respectively. The efficacy of treatment with 
6mg/kg epidoxorubicin applied intravenously com- 
bined with 30 mg kg - 1 day- 1 dexniguldipine adminis- 
tered orally for 3 days prior to epidoxorubicin jection 
was evaluated on tumours grown under the renal cap- 
sule. Dexniguldipine alone did not show antitumour 
effects in vivo. Dexniguldipine modestly, but consis- 
tently, potentiated the tumour-growth-inhibiting effect 
of epidoxorubicin, reaching statistical significance in 
two out of four experiments. In conclusion, these ex- 
periments show that dexniguldipine has potency as an 
MDR reverter in vitro and in vivo in this solid MDR 
tumour model. 
W. Van de Vrie - A. M. M. Eggermont (~)  
Department of Surgical Oncology, Rotterdam Cancer Institute, 
Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. 
Fax: 31 10 4864645 
W. Van de Vrie 9 N. M. C. Durante . A. M. M. Eggermont 
Laboratory for Experimental Surgery, Erasmus University, 
PO Box 1738, 3000 DR Rotterdam, The Netherlands 
J. H. M. Schellens 9 W. J. Loos 9 H. J. Kolker ' J. Verwey . 
G. Stoter 
Department of Medical Oncology, Rotterdam Cancer Institute, 
Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands 
Key words Chemosensitizer 9 Dexniguldipine 9
Epidoxorubicin 9Multidrug resistance 9in vivo 
Abbreviations MDR multidrug resistance 9PBS 
phosphate-buffered saline 
Introduction 
Multidrug resistance (MDR) is an important mecha- 
nism in clinical drug resistance and expression of the 
mdr gene is found in a variety of tumours (Bellamy and 
Dalton 1994; Goldstein et al. 1989). In MDR a trans- 
membrane fflux pump, P-glycoprotein, confers drug 
resistance on a group of chemically unrelated antican- 
cer drugs by increasing the efftux. The P-glycoprotein 
pump can be blocked reversibly by so-called chemosen- 
sitizers, which are substrates for the protein themselves. 
As a result, higher intracellular levels of anticancer 
drugs are achieved and enhanced cell death occurs. 
Among the various compounds that can function as 
chemosensitizers are verapamil, cyclosporin A and its 
non-immunosuppressive analogue PSC 833, quinidine, 
tamoxifen, and many others (Bellamy and Dalton 
1994). Previous studies have been carried out with 
verapamil, but levels necessary for modulation of MDR 
in vivo appeared too high, resulting in severe cardio- 
vascular side-effects. In a clinical trial with verapamil, 
dose-limiting side-effects were hypotension and cardiac 
arrhythmias at levels of exposure anticipated to be 
inadequate for MDR reversal (Pennock et al. 1991). 
This has led to a search for related compounds that are 
devoid of the cardiovascular side-effects. 
Stereoisomers of verapamil and related rugs vary in 
calcium-channel-blocking activity. For example, the 
(+)stereoisomer of verapamil is a 10-fold less potent 
calcium antagonist than the (-) isomer (Echizen et al. 
1985), but has approximately the same chemosensitiz- 
ing effectiveness (Plumb et al. 1990). Of the other 
calcium antagonists, the dihydropyridine drug 
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niguldipine, was found to be a very effective chemosen- 
sitizer in MDR (H611t et al. 1992). The (-)stereoisomer, 
dexniguldipine hydrochloride (B8509-035), displays 
a 45-fold lower affinity for calcium-channel-binding 
sites compared to the (+)isomer, while both have the 
same MDR-modulating potency (H611t et al. 1992). In 
various preclinical models in vitro the chemosensitizing 
potency of dexniguldipine was either equal to or up to 
50 times more effective than verapamil (Hill and Hosk- 
ing 1994; Hofmann et al. 1991, 1992; H611t et al. 1992; 
Reymann et al. 1993; Roller et al. 1993). 
We tested the activity of dexniguldipine in the CC531 
MDR tumour model. CC531 is a colon carcinoma, 
derived from and transplantable in the WAG/RIJ rat, 
that intrinsically expresses the multidrug-resistant 
phenotype. In a previous report the potency of cyclo- 
sporin A as a modulator of resistance to doxorubicin 
was shown in this model (Van de Vrie et al. 1993). Here 
we report on the chemosensitizing effect of dexnigul- 
dipine in vitro and in vivo and on levels of dexnigul- 
dipine and its active metabolite M-1 in plasma and 
tumours. 
Materials and methods 
Animals 
Male rats of the inbred WAG/RIJ (RT1 ") strain were obtained from 
Harlan-CPB (Austerlitz, The Netherlands). Animals were bred un- 
der specific-pathogen-free conditions and fed standard rat chow 
(Hope Farms, Woerden, The Netherlands) and water ad Iibitum. In 
the experiments rats 12-18 weeks old, weighing 220-280 g, were 
used. 
Chemicals 
Dexniguldipine hydrochloride (B8509-035), the metabolite M-1 
(B8909-008) and B89003-001 (internal standard for dexniguldipine 
in the HPLC) were kindly provided by Byk Gulden, Konstanz, 
Germany; epidoxorubicin (Farmorubicin) was obtained from Far- 
mitalia, Carlo Erba, Italy; sulphorhodamine B (SRB) was purchased 
from Sigma Chemicals, St. Louis, M., USA; deionized Milli-Q water 
was from Millipore, Etten Leur, The Netherlands; trichloroacetic 
acid from J.T. Baker, Deventer, The Netherlands; and dichloro- 
methane/hexane/isobutyl alcohol (40:60:0.5) from Rathburn, Wal- 
kerburn, Scotland. 
In vitro cytotoxicity assay 
Chemosensitivity in vitro was determined with the sulpho- 
rhodamine B cell-viability assay, essentially carried out as described 
by Skehan et al. (1990). In brief, 2 x 103 trypsinized tumour cells/well 
in 200 pl complete medium were plated into 96-well flat-bottomed 
microtitre plates (Costar, Cambridge, Mass., USA). Tests were car- 
ried out in quadruplicate. The plates were incubated for 24 h at 
37~ 5% COj95% air to allow the cells to adhere. Then the old 
medium was replaced by medium containing the test drug in graded 
concentrations; in the interaction studies epidoxorubicin together 
with a fixed concentration of dexniguldipine was added. On day 
7 the incubation was terminated by washing the plates twice with 
phosphate-buffered saline (PBS). Subsequently the cells were fixed 
with 10% trichloroacetic a id in deionized Milli-Q water and placed 
for 1 h at 4~ After five washings with tap water, the cells were 
stained for 15 min with 0.4% sulphorhodamine B dissolved in 1% 
acetic acid, and subsequently washed with 1% acetic acid to remove 
the unbound stain. The plates were air-dried and bound protein 
stain was dissolved in 150 gl 10 mM TRIS base. The absorbance 
was read at 540 nm using an automated microplate reader (Titertek, 
Flow Laboratories Ltd., Irvine, Scotland). 
In vivo assay 
Tumour and cell line 
CC531 is a colon carcinoma, which was induced chemically in the 
WAG/RIJ rat with 1,2-dimethylhydrazine. The turnout, a moder- 
ately differentiated adenocarcinoma, is weakly immunogenic and 
transplantable in WAG/RIJ rats (Marquet et al. 1984). In vitro the 
cell line grows as a monolayer. CC531 is an intrinsically multidrug- 
resistant tumour as it expresses the MDR phenotype. At the mRNA 
level, expression ofrndr-la, and not mdr-lb, has been detected by the 
polymerase chain reaction (De Greef et al. 1995). A low level of 
P-glycoprotein expression has been shown with the monoclonal 
antibody C-219 by Western blotting and by immunofluorescence 
techniques (De Greef et al. 1995; Van de Vrie et al. 1993). Intracellu- 
lar accumulation of daunorubicin can be enhanced by chemosen- 
sitizers like verapamil and cyclosporin A (Gheuens et al. 1993; 
Van de Vrie et al. 1993). Cytotoxicity assays have shown the 
typical drug-resistance pattern of MDR and enhancement of
cytotoxicity by chemosensitizers (Gheuens et al. 1993; Van de Vrie 
et al. 1993). 
The cell line was grown in Dulbecco's modified Eagle's medium 
supplemented with 5% fetal calf serum, aspartic acid (0.1 raM), 
glutamic acid (0.3 mM), penicillin (111 IU/ml) and streptomycin 
(111 ~tg/ml), all obtained from Gibco (Paisley, UK), in a humidified 
atmosphere of 5% CO2/95% air at 37~ Regular screening for 
MycopIasma infection was performed. Cells were isolated by trypsin- 
ization; viability, determined by trypan blue exclusion, was over 
90% in all experiments. 
Subcutaneously grown solid tumours of the CC531 cell line were 
used 20-30 days after implantation. In a subrenal capsule assay 
tumour pieces weighing 6-8 mg were implanted under the capsule of 
the kidneys. In the pharmacokinetic experiment, reatment with 
dexniguldipine was given 10 days after implantation. Rats were 
restrained from food 12 h prior to administration of the drug. 
A single dose of 30 mg/kg dexniguldipine was administered orally 
through a thin metal cannula. Five hours later rats were sacrificed, 
a blood sample was taken and the tumours were collected for 
analysis of dexniguldipine and M-1 levels. 
In the pharmacodynamic experiment dexniguldipine treatment 
was started 24 h after implantation of the tumour. In contrast to the 
single dosing in the pharmacokinetic experiment, dexniguldipine 
was administrated for 3 consecutive days orally at a dose of 
30 mg kg- 1 day 1. On day 4, 5 h after the last dexniguldipine dose, 
rats were injected intravenously with 6 mg/kg epidoxorubicin, or
PBS in control rats. On day 10 animals were sacrificed, tumours 
were enucleated and weighed. 
All experimental groups consisted of 6 8 rats. 
Apparatus for dexniguldipine and M-1 measurement 
Dexniguldipine was determined in plasma and tumour tissue with 
an automated reverse-phase isocratic high-performance liquid 
chromatography (HPLC) assay with UV detection at 230 nm. 
A model 710B WISP autosampler and a model M510 pump were 
used (all Waters Assoc., Milford, Mass., USA). The detector was 
a UV2000 (Spectra Physics, San Jose, Calif, USA). The data were 
processed with a Shimadzu CR3A integrator (Shimadzu Corp., 
Kyoto, Japan). The column was a Shandon Hypersyl CPS, 3 I-tm 
150 x 4.6 mm (LC Services, Emmen, The Netherlands). The eluent 
consisted of a 5 mM phosphate buffer (pH 7.5) with 60% aceto- 
nitrite. The flow rate was 1.5 ml/min and the column temperature 
40~ Sample size was 100 ~tl for each analysis. 
Sample preparation for dexniguldipine and M-1 measurement. 
A volume of 150 gl plasma was collected, to which 50 pl 2000ng/ml 
solution of internal standard (B89003-001) in methanol was added. 
Next, 800 gl deionized Milli-Q water was added and the sample was 
mixed on a whirl mixer for 15 s. For extraction of the test chemicals 
7 ml dichloromethane/hexane/isobutyl alcohol (40:60:0.5) was ad- 
ded. The mixture was mixed for 30 min on a whirl mixer and 
subsequently centrifuged for 10 min at 4000 g. The organic layer 
was collected and evaporated to dryness at 50~ under vacuum. The 
residue was reconstituted in 150 gl eluent. 
Tumour tissue was homogenized with a Turrax homogenizer 
(Boom, Meppel, The Netherlands) in 1 ml Milli-Q water. The hom- 
ogenizer was flushed twice with 250 lal Milli-Q water. A 50-gl 
volume of a 2000-ng/ml internal standard solution in methanol and 
7 ml dichloromethane/hexane/isobutyl alcohol (40:60:0.5) were ad- 
ded. Further handling of the tissue sample was as described for the 
plasma sample. 
The recovery of dexniguldipine, M-l, and the internal standard 
was determined relative to direct injection of the individual dis- 
solved compounds. 
Statistics 
Statistical analysis was carried out with SPSS/PC+, using the 
Mann-Whitney U/Wilcoxon rank-sum W-test. P < 0.05 was con- 
sidered significant. 
Ethical approval 
The experimental protocols adhered to the rules laid down in The 
Dutch Animal Experimentation Act (1977) and the Guidelines on the 
Protection of Experimental Animals published by the Council of the 
E.C. (1986). Specific protocols were approved by the Committee on 
Animal Research of the Erasmus University, Rotterdam. 
Results 
In vitro chemosensitizing effect of dexniguldipine 
on epidoxorubicin 
Dexniguldipine up to 1000 ng/ml had less than 10% 
growth-inhibiting effect on CC531 cells in vitro. The 
median inhibitory dose (IDs0) for dexniguldipine was 
approximately 5000 ng/ml. Epidoxorubicin showed 
a concentration-dependent growth-inhibiting effect 
with an ID50 of 62 ng/ml. The chemosensitizer dex- 
niguldipine at a concentration of 50 ng/ml enhanced 
cytotoxicity of epidoxorubicin approximately 15 times 
(Fig. 1). Higher concentrations of dexniguldipine were 
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Fig. 1 Dose/response curves of the cell line CC531 to incubation 
with graded concentrations of epidoxorubicin the absence (G) or 
presence ( , )  of the chemosensitizer dexniguldipine (50 ng/ml) deter- 
mined in the sulphorhodamine cell viability assay. Sulpho- 
rhodamine B absorbance is expressed as a percentage ofthe control 
absorbance on the y axis and represents he percentage c ll viability. 
equally effective (500 ng/ml) or too toxic for CC531 
cells by themselves (5000 ng/ml) (data not shown). 
Tissue concentrations of dexniguldipine 
In this report we show some data on the levels of 
dexniguldipine and M-1 in plasma and in tumour tis- 
sue. In a separate report more elaborate studies on 
dexniguldipine and M-1 pharmacokinetics will be pre- 
sented. (JHM Schellens, et al., manuscript in prepara- 
tion). Dexniguldipine was readily absorbed after oral 
administration reaching levels in plasma after 5 h of 72 
( _+ 19 SD) ng/ml. (see Fig. 2). Levels in tumour tissue 
were much higher: 925 (_+ 495 SD) ng/g. A similar 
pattern was observed for the metabolite M-l: in plasma 
26 ( + 6 SD) ng/ml and in tumour tissue 289 (___ 127 
SD) ng/g. The level of M-1 was approximately one- 
third of the level of dexniguldipine. 
In vivo chemosensitizing effect of dexniguldipine 
on epidoxorubicin 
Pilot experiments with epidoxorubicin alone showed 
that a dose of 6 mg/kg had a moderate but consistent 
growth-inhibiting effect on CC531 tumours grown in 
the subrenal capsule assay. Dexniguldipine treatment 
alone had no influence on growth of the tumour. In all 
experiments, tumours treated with the combination 
dexniguldipine and epidoxorubicin were the smallest 
and statistical significance was reached in two experi- 
ments. The results are shown in Table 1. Dexnigul- 
dipine had no additive effect in combination with 
a lower dose of 4 mg/kg epidoxorubicin (data not 
shown). 
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Fig. 2 Dexniguldipine (D) and M-1 (V) levels in plasma (ng/ml) and 
tumour tissue (ng/g) determined by HPLC 5 h after a single oral 
dose of 30 mg/kg. Results from rats are represented individually on 
a logarithmic scale, with lines indicating the mean values. Left data 
from plasma; right data from tumour tissue 
The experiments were not specifically designed 
for assessment of toxicity, but some effects on the 
body weight of rats were observed. Data on body 
weights were available from three experiments. All 
rats lost some weight during the experiment: control 
rats 1%-5%, dexniguldipine-treated rats 2%-6%, 
rats treated with epidoxorubicin alone 8%-12%, and 
rats treated with the combination dexniguldipine and 
epidoxorubicin 9%-13%. The total weight loss was 
significantly higher in the rats treated with epi- 
doxorubicin compared to control groups. In one of the 
three experiments, rats treated with the combination 
dexniguldipine and epidoxorubicin had significantly 
more weight loss compared to epidoxorubicin-treated 
rats. In this particular experiment (number 3) no differ- 
ence was observed in tumour weights between these 
groups. 
Discussion 
Dexniguldipine is a novel modulator of MDR that has 
low intrinsic calcium antagonist activity. In vitro stud- 
ies have shown its efficacy as a chemosensitizer in 
various cytotoxicity tests and accumulation assays 
(Hill and Hosking 1994; Hofmann et al. 1991, 1992; 
H611t et al. 1992; Reymann et al. 1993; Roller et al. 
1993). Effective chemosensitizing was shown in experi- 
mental and in human tumour cell lines, and in induced 
as well as in intrinsic MDR. On a molar basis dexnigul- 
dipine was shown to be at least as effective as 
verapamil. Most studies report a superior drug-modu- 
lating effect of dexniguldipine over verapamil of 2.5- to 
50-fold (Hill and Hosking 1994; Hofmann et al. 1992; 
Reymann et al. 1993; Roller et al. 1993). 
This study expands these in vitro studies with in vivo 
data. After oral administration, dexniguldipine is read- 
ily absorbed and distributed into various tissues. Dex- 
niguldipine has a very lipophilic nature and its volume 
of distribution ishigh (in animals 20-40 1/kg) (Zech and 
Herzog 1991). In the present study intratumoural levels 
of dexniguldipine were 925 ng/g tissue, which is more 
than ten times the plasma levels. Compared to the in 
vitro level of 50 ng/ml, which was effective in MDR 
modulation, these in vivo levels are high. The data on 
dexniguldipine l vels were obtained after a single oral 
dosing. In the antitumour experiment dosing was 
tripled by administration on 3 consecutive days. Be- 
cause of the lipophilic nature of the drug this will 
probably have resulted in even higher intratumoural 
levels. The wide variation in the results of the levels of 
the chemosensitizer is not readily explained. Wide in- 
terindividual variation in pharmacokinetics has been 
reported by others for dexniguldipine after oral admin- 
istration, as well as for other dihydropyridine com- 
pounds (Ukena et al. 1995). 
Part of the activity of dexniguldipine in vivo is me- 
diated by the active metabolite M-l, which is shown to 
have the same MDR-modulating potency as dexnigul- 
dipine (Hofmann et al. 1992; H611t et al. 1992). The 
pharmacokinetics of M-1 followed the results of 
Table 1 Results of experiments 
(1-4) on tumour growth 
inhibition in vivo with 
epidoxorubicin and the 
chemosensitizer dexniguldipine. 
Standard eviations are shown 
in parentheses 
Treatment group Tumour weight (rag) 
1 2 3 4 
Control 45.1 ( _+ 15.6) 34.4 ( + 7.8) 20.8 ( _+ 6.5) 41.3 ( • 9.2) 
Dexniguldipine 38.6 ( _+ 17.9) 35.1 ( ___ 9.0) 16.4 ( _+ 10.6) 40.6 ( _+ 14.9) 
Epidoxorubicin 6 mg/kg 23.2 ( • 2.5)* 20.9 ( • 3.2)** 12.3 ( • 4.2)* 27.2 ( • 5.1)* 
Epidoxorubicin 6 mg/kg 
+ dexniguldipine 18.5 ( i 10.2)** 13.9 ( _+ 4.7)**'*** 9.9 ( - 4.1)* 19.6 ( _+ 5.2)**'*** 
- Statistically significant (P < 0.05) results: * epidoxorubicin or epidoxorubicin + dexniguldipine 
versus control; **epidoxorubicin or epidoxorubicin + dexniguldipine v rsus control and versus dex- 
niguldipine; ***epidoxorubicin + dexniguldipine v rsus epidoxorubicin 
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dexniguldipine closely. The M-1 level was approxim- 
ately one-third of the level of dexniguldipine in plasma 
and in tumour tissue 5 h after administration. Recently, 
comparable levels of dexniguldipine and M-1 have 
been published from a phase I trial in patients (Ukena 
et al. 1995). 
Dexniguldipine showed no direct antitumour activ- 
ity against CC531 cells. Antiproliferative effects of dex- 
niguldipine have been reported for some tumours, pos- 
sibly tumours with a neuroendocrine differentiation 
depending on autocrine stimulating factors (Schiiller et 
al. 1990, 1991). The chemosensitizing potency of dex- 
niguldipine on the MDR CC531 tumour was observed 
in all in vivo experiments. Dexniguldipine had a signifi- 
cant potentiating effect on growth inhibition of CC531 
tumours by epidoxorubicin two out of four experi- 
ments, while in the other experiments the observed 
differences did not reach statistical significance. The 
results with dexniguldipine are comparable to those 
with earlier published experiments in the CC531 tu- 
mour model, which revealed the chemosensitizing effect 
of cyclosporin A in combination with doxorubicin (Van 
de Vrie et al. 1993). 
Levels of epidoxorubicin  plasma nd tumour have 
not been measured in these experiments. Therefore, we 
cannot rule out the possibility that altered phar- 
macokinetics of epidoxorubicin contribute to the 
chemosensitizing effect apart from direct modulation of 
MDR at the cellular level. The fact that combination 
treatment resulted in a small enhancement of oxicity in 
one experiment, as measured by body-weight loss, sug- 
gests that at least some systemic enhancement of epi- 
doxorubicin activity may have occurred. This is in 
agreement with previous tudies that showed enhance- 
ment of doxorubicin toxicity caused by combined treat- 
ment with cyclosporin A (Van de Vrie et al. 1994). 
Other investigators, however, have also furnished 
evidence for a direct effect of chemosensitizers on the 
tumour. Niwa et al. showed that PAK-200, like dex- 
niguldipine a dihydropyridine analogue, enhanced the 
accumulation of doxorubicin in solid turnouts in vivo 
(Niwa et al. 1992). The effect of PAK-200 on doxorubicin 
accumulation i the tumours was dependent on the 
level of P-glycoprotein expression: only the tumours 
with a clear expression of P-glycoprotein had a higher 
doxorubicin content in the presence of the chemosen- 
sitizer. Furthermore, in patients with refractory mul- 
tiple myeloma, addition of cyclosporin A to the 
chemotherapeutic regimen vincristine, doxorubicin and 
dexamethasone resulted in enhancement of the response 
rate (Sonneveld et al. 1992). Additional studies howed 
that the effect was probably achieved by specific killing 
of the plasma cells expressing P-glycoprotein (Son- 
neveld et al. 1994). The studies clearly suggest drug 
modulation directly at the cellular level by a P-glyco- 
protein-dependent mechanism. 
The results in our study are comparable to results 
obtained with dexniguldipine and doxorubicin in 
a nude mouse xenograft model. Here partial reversal of 
resistance to doxorubicin was observed in solid tu- 
mours of the MDRl-overexpressing KB 8.5 cell line 
grown subcutaneously (Boss et al. 1994). Dexnigul- 
dipine has entered clinical studies now and promising 
results have been obtained in trials in acute myeloid 
leukemia nd multiple myeloma (Scheulen et al. 1995; 
Thaler et al. 1994). 
The present study confirms the chemosensitizing po- 
tency of dexniguldipine on MDR cells in vitro. It shows 
that in vivo relatively high levels of dexniguldipine in
plasma and tumour tissue can easily be achieved by 
oral administration. In vivo this resulted in a strong 
trend towards a significant enhancement of the anti- 
tumour effect of epidoxorubicin in the solid MDR 
tumour CC531. 
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